2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow alpha-Thalassemia: new trials by email Literature Review of alpha-Thalassemia trials Research Report on alpha-Thalassemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study deferasirox, placebo - Non-transfusion Dependent Thalassemia | Phase 2 | Completed | Novartis Pharmaceuticals | 166 | 2008-11-01 | 2013-07-09 |
Thalassemia (2) · beta-Thalassemia (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Sickle Cell (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Hemolysis (1) · Iron Overload (1) · Sickle Cell Trait (1) · Vaso-Occlusive Crises (1)
Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Hemic and Lymphatic Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Iron Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Deferasirox (1)
Forma Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1)
Italy (2) · Lebanon (2) · United Kingdom (2) · United States (2) · Canada (1) · Egypt (1) · Greece (1) · Malaysia (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)